Relmada Therapeutics, Inc. RLMD Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect?
- Relmada Therapeutics, Inc. (RLMD) reported cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect of $6.28M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect changed year-over-year?
- Relmada Therapeutics, Inc.'s cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect increased by 332.0% year-over-year, from -$2.71M to $6.28M.
- What does cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect mean?
- The net change in the total balance of cash, cash equivalents, and restricted cash over a specific period, excluding the effects of foreign currency exchange rates. It provides a comprehensive view of the company's overall cash flow health and liquidity position.